Investors Alert: Class Action Lawsuit Filed Against Applied Therapeutics, Inc. with a Deadline Approaching

Class Action Lawsuit Against Applied Therapeutics, Inc.

On February 18, 2025, Levi & Korsinsky, LLP warns investors of a class action securities lawsuit against Applied Therapeutics, Inc. (NASDAQ: APLT). This legal action addresses significant losses suffered by investors during a specified period impacted by alleged securities fraud, primarily affecting investors from January 3, 2024, to December 2, 2024.

Background of the Case

The foundation for this lawsuit stems from recent communications by Applied Therapeutics. On November 27, 2024, the company disclosed it had received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for govorestat, its leading drug candidate. The CRL indicated that the FDA found deficiencies in the clinical application, which led to a rapid decline in the company’s stock price—falling from $10.21 per share down to as low as $1.29 within days.

The decline continued when it became public that the company received a 'warning letter' from the FDA, revealing deeper issues with its clinical trials. The significant drop in share prices, which saw losses of over 80%, has raised serious concerns among investors about the integrity of the company's communications and the management of its clinical trials.

Who Can Join the Class Action?

If you are an investor who faced losses due to these circumstances, you can request to be appointed as a lead plaintiff in this class action lawsuit by the deadline of February 18, 2025. However, it’s important to note that participating in the class does not necessitate this role; investors can still benefit from any possible recovery without serving as lead plaintiffs.

No Cost for Class Members

The lawsuit also emphasizes that participating in this class action incurs no out-of-pocket expenses for the class members. Investors drawn into this case can seek compensation without any upfront fees, ensuring that financial barriers do not hinder participation.

Levi & Korsinsky's Commitment

Levi & Korsinsky is well-regarded for its track record, having secured considerable settlements for investors and ranking among the top securities litigation firms in the U.S. Their expertise spans over two decades, specializing in complex securities cases, providing investors with a robust legal resource during challenging times.

If you believe you have been impacted by this situation, visit their website or contact them directly. The potential for significant financial recovery exists for those affected by Applied Therapeutics’ actions.

How to Get Involved

For those interested, more information is available at their dedicated class action webpage. You can also reach out directly to Joseph E. Levi, Esq. via email or phone as provided earlier. Prompt action is advised to ensure your ability to recover losses suffered between the identified dates.

In conclusion, this lawsuit highlights the risks associated with investing in pharmaceuticals, particularly regarding compliance with regulations and transparency with shareholders. Stay informed, and if affected, consider joining this crucial class action before the approaching deadline.